Lionsgate Studios Corp Common Shares vs Stryker Corporation — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B), while Stryker Corporation trades at $285 (market cap $108.38B). The key difference: Stryker Corporation is far larger — about 32.7× Lionsgate Studios Corp Common Shares's market cap, and Stryker Corporation pays a 1.25% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Stryker Corporation for 22 Days on average.
| LION | SYK | |
|---|---|---|
Market Cap | $3.31B | $108.38B |
Volume | 2,146,134 | 2,068,363 |
Sector | Technology | Health |
52-Week High | $16.40 | $388.35 |
52-Week Low | $5.91 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $6.82B | $119.84B |
Dividend Yield | — | 1.25% |
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →